FDA Should Turn Over AE Analysis Criteria To Firms – Boston Scientific Exec
This article was originally published in The Gray Sheet
Executive Summary
Much of the analysis of device-related adverse event reports currently handled by FDA could be completed by device manufacturers if the agency provided the criteria, according to Boston Scientific Manager for Quality and Regulatory Compliance Kristin Johnson